LAUSR

Cancer is increasingly important in low and middle‐income settings where infectious diseases are declining. Childhood cancers treated in well‐resourced centres have excellent outcomes with more than 80% survival. This success is not reflected in low‐income settings where challenges involve every step on the care pathway. Access to diagnosis, delayed presentation, advanced disease, co‐morbidities and underlying malnutrition make treatment difficult. Treatments are costly for impoverished families. Yet, the common haematological malignancies (Burkitt lymphoma, Hodgkin lymphoma, non Hodgkin lymphoma) are relatively easy to diagnose and, when managed with simple chemotherapy protocols, give limited but good results. As funding becomes available for cancer research we must ensure that the care and cure of these children is top of the agenda. There is already evidence of improved outcomes in middle‐income countries. For others there is a long journey ahead.